Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
University of California San Francisco, San Francisco, California Wake Forest Institute for Regenerative Medicine (WFIRM), Winston-Salem, North Carolina